PUBLISHED BY
Vionnet, Julien; Miquel, Rosa; Abraldes, Juan G.; Wall, Jurate; Kodela, Elisavet; Lozano, Juan-Jose; Ruiz, Pablo; Navasa, Miguel; Marshall, Aileen; Nevens, Frederik; Gelson, Will; Leithead, Joanna; Masson, Steven; Jaeckel, Elmar; Taubert, Richard; Tachtatzis, Phaedra; Eurich, Dennis; Simpson, Kenneth J.; Bonaccorsi-Riani, Eliano; Feng, Sandy; Bucuvalas, John; Ferguson, James; Quaglia, Alberto; Sidorova, Julia; Elstad, Maria; Douiri, Abdel; Sánchez-Fueyo, Alberto
PUBLISHED IN
Journal of Hepatology
PATIENTS
190
ABSTRACT
HIGHLIGHTS
- Study assessed non-invasive tools for stratifying liver transplant recipients' immunological risk and immunosuppression needs.
- 190 stable adult LT recipients with non-autoimmune, non-replicative viral liver disease assessed using various histological and serological tests and an 11-gene TCMR classifier.
- 35.8% of patients had silent fibro-inflammatory liver lesions, with damage severity linked to TCMR transcripts, class II DSAs, ALT, AST, and LSM, and inversely with serum creatinine and tacrolimus levels.
- Two prediction models (ALT+LSM and ALT+class II DSAs) effectively distinguished patients with and without alloimmune damage, validated in a separate cohort of 156 paediatric liver biopsies.
- ALT, class II DSAs, and LSM are valuable non-invasive tools for identifying LT recipients who might safely reduce immunosuppression.
